Meeting
2021 ASCO Annual Meeting
Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.
Authors
Malcolm Isaiah Ryan
Princess Margaret Cancer Centre, Toronto, ON, Canada
Malcolm Isaiah Ryan , Jessica Weiss , Aline Fusco Fares , Ming Sound Tsao , Geoffrey Liu , Penelope Ann Bradbury , Natasha B. Leighl , Frances A. Shepherd , Adrian G. Sacher , Sally C. M. Lau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8547)
DOI
10.1200/JCO.2021.39.15_suppl.8547
Abstract #
8547
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2023 ASCO Annual Meeting
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
First Author: Fabrice Barlesi
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo
Poster
2022 ASCO Annual Meeting
Effect of durvalumab in patients with unresectable stage 3 non–small cell lung cancer post-chemoradiotherapy.
First Author: Aswani Thurlapati